Rexahn Pharmaceuticals, Inc. (RNN) Downgraded by Zacks Investment Research to Hold
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
Separately, FBR & Co reiterated an outperform rating and set a $3.00 price target on shares of Rexahn Pharmaceuticals in a research report on Wednesday, October 5th.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.20 on Wednesday. The firm has a 50-day moving average price of $0.23 and a 200-day moving average price of $0.27. Rexahn Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $0.52. The stock’s market cap is $42.66 million.
Rexahn Pharmaceuticals (NYSE:RNN) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Equities analysts forecast that Rexahn Pharmaceuticals will post ($0.07) EPS for the current year.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. increased its position in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned about 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent reporting period.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Stock Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.